Company Announcement
COPENHAGEN, Denmark; June 16, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 185 shares as a consequence of the exercise of employee warrants.
The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:
185 shares at DKK 1,334.50.
Proceeds to the Company are approximately DKK 0.2 million. The increase corresponds to less than 0.001%of the Company’s share capital.
The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.
Pursuant to section 32 of the Danish Capital Markets Act No. 464 of May 1, 2026, it is hereby announced, that the total nominal value of Genmab A/S’ share capital after the capital increase is DKK 62,353,252 which is made up of 62,353,252 shares of a nominal value of DKK 1 each, corresponding to 62,353,252 votes.
About Genmab
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.
Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across
